Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China has the most crowded immune checkpoint inhibitors market globally with 12 approved therapies and many more in development, encouraged by the ongoing reforms in China’s regulatory and access and reimbursement landscape. The growing incorporation of these agents in the treatment paradigm for many cancers has led to significant growth of China’s immune checkpoint inhibitor market over the last few years. Moreover, the incorporation of four domestic immune checkpoint inhibitors—sintilimab (Innovent Bio's Tyvyt), camrelizumab (Hengrui Medicine's AiRuiKa), tislelizumab (BeiGene's Baize’an), and toripalimab (Junshi Bio's TuoYi)—into China’s National Reimbursement Drug List (NRDL) has greatly improved patient access. Based on the rising use, rich pipeline, and improving access and reimbursement of immune checkpoint inhibitors in the country, we anticipate that China will become a market leader in the immune checkpoint inhibitors space during the forecast period.
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in select oncology indications.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 oncologists
10-year, annualized, drug-level sales of key immune checkpoint inhibitors through 2031, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 14 drugs